ATE302267T1 - Transgenes kaninchen, dass ein funktionelles menschliches lipoprotein(a) exprimiert - Google Patents
Transgenes kaninchen, dass ein funktionelles menschliches lipoprotein(a) exprimiertInfo
- Publication number
- ATE302267T1 ATE302267T1 AT99904051T AT99904051T ATE302267T1 AT E302267 T1 ATE302267 T1 AT E302267T1 AT 99904051 T AT99904051 T AT 99904051T AT 99904051 T AT99904051 T AT 99904051T AT E302267 T1 ATE302267 T1 AT E302267T1
- Authority
- AT
- Austria
- Prior art keywords
- expresses
- rabbit
- functional human
- transgenic rabbit
- human lipoprotein
- Prior art date
Links
- 241000283973 Oryctolagus cuniculus Species 0.000 title abstract 4
- 230000009261 transgenic effect Effects 0.000 title abstract 2
- 101000889990 Homo sapiens Apolipoprotein(a) Proteins 0.000 title 1
- 102000045903 human LPA Human genes 0.000 title 1
- 102100040214 Apolipoprotein(a) Human genes 0.000 abstract 3
- 101710095342 Apolipoprotein B Proteins 0.000 abstract 1
- 102100040202 Apolipoprotein B-100 Human genes 0.000 abstract 1
- 101710115418 Apolipoprotein(a) Proteins 0.000 abstract 1
- 108010012927 Apoprotein(a) Proteins 0.000 abstract 1
- 108010033266 Lipoprotein(a) Proteins 0.000 abstract 1
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/775—Apolipopeptides
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
- A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/107—Rabbit
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0375—Animal model for cardiovascular diseases
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S977/00—Nanotechnology
- Y10S977/902—Specified use of nanostructure
- Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
- Y10S977/924—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis using nanostructure as support of dna analysis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Environmental Sciences (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Husbandry (AREA)
- General Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Biodiversity & Conservation Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Pathology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7072798P | 1998-01-08 | 1998-01-08 | |
PCT/US1999/000401 WO1999035241A1 (en) | 1998-01-08 | 1999-01-08 | Transgenic rabbit that expresses a functional human lipoprotein (a) |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE302267T1 true ATE302267T1 (de) | 2005-09-15 |
Family
ID=22097023
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT99904051T ATE302267T1 (de) | 1998-01-08 | 1999-01-08 | Transgenes kaninchen, dass ein funktionelles menschliches lipoprotein(a) exprimiert |
Country Status (12)
Country | Link |
---|---|
US (1) | US6512161B1 (de) |
EP (1) | EP1049767B1 (de) |
JP (2) | JP2002500039A (de) |
AT (1) | ATE302267T1 (de) |
AU (1) | AU759707B2 (de) |
CA (1) | CA2316808C (de) |
DE (1) | DE69926729T2 (de) |
DK (1) | DK1049767T3 (de) |
ES (1) | ES2247780T3 (de) |
PT (1) | PT1049767E (de) |
WO (1) | WO1999035241A1 (de) |
ZA (1) | ZA99133B (de) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1122314A1 (de) * | 2000-02-04 | 2001-08-08 | Leja Research B.V. | Verfahren zur Herstellung von Proteinen |
US7888324B2 (en) | 2001-08-01 | 2011-02-15 | Genzyme Corporation | Antisense modulation of apolipoprotein B expression |
US7407943B2 (en) * | 2001-08-01 | 2008-08-05 | Isis Pharmaceuticals, Inc. | Antisense modulation of apolipoprotein B expression |
US7259150B2 (en) * | 2001-08-07 | 2007-08-21 | Isis Pharmaceuticals, Inc. | Modulation of apolipoprotein (a) expression |
AU2012258396B2 (en) * | 2001-08-07 | 2015-05-07 | Isis Pharmaceuticals, Inc. | Antisense modulation of apolipoprotein (a) expression |
US7227014B2 (en) * | 2001-08-07 | 2007-06-05 | Isis Pharmaceuticals, Inc. | Antisense modulation of apolipoprotein (a) expression |
DK1534320T3 (da) | 2002-08-02 | 2007-04-02 | Univ Bruxelles | Apolipoprotein L-I til behandling af trypanosomen sygdomme |
US20040033480A1 (en) * | 2002-08-15 | 2004-02-19 | Wong Norman C.W. | Use of resveratrol to regulate expression of apolipoprotein A1 |
US7511131B2 (en) | 2002-11-13 | 2009-03-31 | Genzyme Corporation | Antisense modulation of apolipoprotein B expression |
US20060009410A1 (en) * | 2002-11-13 | 2006-01-12 | Crooke Rosanne M | Effects of apolipoprotein B inhibition on gene expression profiles in animals |
CA2556697C (en) * | 2004-02-17 | 2018-01-09 | Nielsen Media Research, Inc. | Methods and apparatus for monitoring video games |
US20050287558A1 (en) * | 2004-05-05 | 2005-12-29 | Crooke Rosanne M | SNPs of apolipoprotein B and modulation of their expression |
PT2409713E (pt) * | 2004-08-10 | 2015-10-09 | Genzyme Corp | Oligonucleótidos para utilização em modulação dos níveis de lipoproteínas e colesterol em humanos |
WO2006045010A2 (en) * | 2004-10-20 | 2006-04-27 | Resverlogix Corp. | Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases |
EP2314295B1 (de) * | 2005-07-29 | 2015-01-28 | Resverlogix, Inc | Arzneimittel zur Prävention und Behandlung komplexer Erkrankungen und deren Freisetzung mittels einsetzbarer Medizinprodukte |
ES2386578T3 (es) | 2006-05-05 | 2012-08-23 | Isis Pharmaceuticals, Inc. | Compuestos y procedimientos para modular la expresión de PCSK9 |
MX2009008099A (es) * | 2007-02-01 | 2009-12-14 | Resverlogix Corp | Compuestos para la prevencion y tratamiento de enfermedades cardiovasculares. |
CN101679979A (zh) * | 2007-03-24 | 2010-03-24 | 基酶有限公司 | 施用与人载脂蛋白b互补的反义寡核苷酸 |
KR101629356B1 (ko) | 2008-06-26 | 2016-06-13 | 리스버로직스 코퍼레이션 | 퀴나졸리논 유도체의 제조방법 |
US20110023140A1 (en) * | 2008-12-04 | 2011-01-27 | Sigma-Aldrich Co. | Rabbit genome editing with zinc finger nucleases |
CA2747417C (en) | 2009-01-08 | 2017-01-03 | Resverlogix Corp. | Compounds for the prevention and treatment of cardiovascular disease |
WO2010107838A1 (en) | 2009-03-16 | 2010-09-23 | Isis Pharmaceuticals, Inc. | Targeting apolipoprotein b for the reduction of apolipoprotein c-iii |
US9238640B2 (en) | 2009-03-18 | 2016-01-19 | Resverlogix Corp. | Anti-inflammatory agents |
BRPI1014956B8 (pt) | 2009-04-22 | 2021-05-25 | Resverlogix Corp | agentes anti-inflamatórios |
CA2770825A1 (en) | 2009-08-13 | 2011-02-17 | Crystal Bioscience Inc. | Transgenic animal for production of antibodies having minimal cdrs |
WO2012141280A1 (ja) | 2011-04-15 | 2012-10-18 | 国立大学法人 大阪大学 | Dnaワクチン |
JP5992049B2 (ja) | 2011-11-01 | 2016-09-14 | レスバーロジックス コーポレイション | 置換されたキナゾリノンのための経口速放性製剤 |
WO2013173789A2 (en) | 2012-05-17 | 2013-11-21 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide compositions |
US9574193B2 (en) | 2012-05-17 | 2017-02-21 | Ionis Pharmaceuticals, Inc. | Methods and compositions for modulating apolipoprotein (a) expression |
DK2855500T3 (da) * | 2012-05-24 | 2020-09-14 | Ionis Pharmaceuticals Inc | Fremgangsmåder og sammensætninger til modulering af apolipoprotein (A)-ekspression |
JP6001974B2 (ja) | 2012-09-21 | 2016-10-05 | アンジェスMg株式会社 | アポリポプロテイン(a)の特異的エピトープを含むDNAワクチン |
WO2014080290A2 (en) | 2012-11-21 | 2014-05-30 | Rvx Therapeutics Inc. | Cyclic amines as bromodomain inhibitors |
WO2014080291A2 (en) | 2012-11-21 | 2014-05-30 | Rvx Therapeutics Inc. | Biaryl derivatives as bromodomain inhibitors |
WO2014096965A2 (en) | 2012-12-21 | 2014-06-26 | Rvx Therapeutics Inc. | Novel heterocyclic compounds as bromodomain inhibitors |
US9018437B2 (en) | 2013-09-12 | 2015-04-28 | Matthias W. Rath | Transgenic mouse expressing human apo(a) and human apo(B-100) with disabled vitamin C gene produces human Lp(a) |
EP3021663B1 (de) * | 2014-10-05 | 2023-01-18 | Matthias W. Rath | Menschliches lipoprotein exprimierende transgene maus mit deaktivierung des vitamin-c-gens |
JP6903585B2 (ja) | 2015-03-13 | 2021-07-14 | レスバーロジックス コーポレイション | 補体関連疾患の治療のための組成物および治療方法 |
EP4237561A1 (de) | 2020-12-23 | 2023-09-06 | Argonaute Rna Limited | Behandlung von herz-kreislauf-erkrankungen |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0467349B1 (de) | 1983-10-20 | 2000-12-27 | The Research Foundation Of State University Of New York | Regulierung der Genexpression durch Translationshemmung unter Verwendung einer m-RNS behindernden komplementären RNS |
GB8424757D0 (en) | 1984-10-01 | 1984-11-07 | Pasteur Institut | Retroviral vector |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
US4861719A (en) | 1986-04-25 | 1989-08-29 | Fred Hutchinson Cancer Research Center | DNA constructs for retrovirus packaging cell lines |
AU3069189A (en) | 1988-02-05 | 1989-08-25 | Trustees Of Columbia University In The City Of New York, The | Retroviral packaging cell lines and processes of using same |
WO1990002806A1 (en) | 1988-09-01 | 1990-03-22 | Whitehead Institute For Biomedical Research | Recombinant retroviruses with amphotropic and ecotropic host ranges |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
CA2039921A1 (en) | 1990-04-16 | 1991-10-17 | Xandra O. Breakefield | Transfer and expression of gene sequences into central nervous system cells using herpes simplex virus mutants with deletions in genes for viral replication |
AU7906691A (en) | 1990-05-23 | 1991-12-10 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | Adeno-associated virus (aav)-based eucaryotic vectors |
US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
US5252479A (en) | 1991-11-08 | 1993-10-12 | Research Corporation Technologies, Inc. | Safe vector for gene therapy |
EP0651805B1 (de) | 1992-07-17 | 2006-12-13 | Dana Farber Cancer Institute | Method eder intrazellularen bindung von zielgerichteten molekülen |
WO1994012649A2 (en) | 1992-12-03 | 1994-06-09 | Genzyme Corporation | Gene therapy for cystic fibrosis |
US5434058A (en) * | 1993-02-09 | 1995-07-18 | Arch Development Corporation | Apolipoprotein B MRNA editing protein compositions and methods |
FR2705361B1 (fr) | 1993-05-18 | 1995-08-04 | Centre Nat Rech Scient | Vecteurs viraux et utilisation en thérapie génique. |
FR2705686B1 (fr) | 1993-05-28 | 1995-08-18 | Transgene Sa | Nouveaux adénovirus défectifs et lignées de complémentation correspondantes. |
US5866755A (en) | 1993-06-14 | 1999-02-02 | Basf Aktiengellschaft | Animals transgenic for a tetracycline-regulated transcriptional inhibitor |
EP0667912B1 (de) | 1993-07-13 | 2008-07-02 | Centelion | Defekte adenovirus-vektoren und deren verwendung in der gentherapie |
US5877399A (en) * | 1994-01-27 | 1999-03-02 | Johns Hopkins University | Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease |
FR2718329B1 (fr) * | 1994-03-21 | 2002-09-20 | Rhone Poulenc Rorer Sa | Lapin transgénique sensibilisé aux dyslipoprotéinémies. |
IL116816A (en) | 1995-01-20 | 2003-05-29 | Rhone Poulenc Rorer Sa | Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof |
-
1999
- 1999-01-08 AU AU24536/99A patent/AU759707B2/en not_active Ceased
- 1999-01-08 DE DE69926729T patent/DE69926729T2/de not_active Expired - Lifetime
- 1999-01-08 AT AT99904051T patent/ATE302267T1/de active
- 1999-01-08 US US09/227,701 patent/US6512161B1/en not_active Expired - Lifetime
- 1999-01-08 WO PCT/US1999/000401 patent/WO1999035241A1/en active IP Right Grant
- 1999-01-08 DK DK99904051T patent/DK1049767T3/da active
- 1999-01-08 EP EP99904051A patent/EP1049767B1/de not_active Expired - Lifetime
- 1999-01-08 CA CA002316808A patent/CA2316808C/en not_active Expired - Fee Related
- 1999-01-08 PT PT99904051T patent/PT1049767E/pt unknown
- 1999-01-08 JP JP2000527627A patent/JP2002500039A/ja active Pending
- 1999-01-08 ZA ZA9900133A patent/ZA99133B/xx unknown
- 1999-01-08 ES ES99904051T patent/ES2247780T3/es not_active Expired - Lifetime
-
2009
- 2009-09-28 JP JP2009223202A patent/JP2010000090A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CA2316808C (en) | 2007-04-10 |
AU2453699A (en) | 1999-07-26 |
WO1999035241A9 (en) | 2000-04-13 |
ES2247780T3 (es) | 2006-03-01 |
DE69926729T2 (de) | 2006-06-08 |
EP1049767B1 (de) | 2005-08-17 |
US6512161B1 (en) | 2003-01-28 |
JP2002500039A (ja) | 2002-01-08 |
WO1999035241A1 (en) | 1999-07-15 |
EP1049767A4 (de) | 2002-05-08 |
EP1049767A1 (de) | 2000-11-08 |
DE69926729D1 (de) | 2005-09-22 |
ZA99133B (en) | 1999-09-16 |
PT1049767E (pt) | 2005-10-31 |
JP2010000090A (ja) | 2010-01-07 |
CA2316808A1 (en) | 1999-07-15 |
AU759707B2 (en) | 2003-04-17 |
DK1049767T3 (da) | 2005-09-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE302267T1 (de) | Transgenes kaninchen, dass ein funktionelles menschliches lipoprotein(a) exprimiert | |
HUP9902571A2 (hu) | Timidin kináz variánsai, ezeket kódoló nukleinsav-szekvenciák és alkalmazásuk génterápiában | |
DE60023936D1 (de) | Methoden zur verwendung von randomisierten zinkfingerprotein-bibliotheken zur identifizierung von genfunktionen | |
ATE323510T1 (de) | Gentherapeutische verfahren zur bereitstellung von apolipoprotein a-i agonisten sowie deren verwendung zur behandlung dyslipidämischer erkrankungen | |
DE60129799D1 (de) | Verfahren zur steigerung des haarwuchses durch wnt polypeptid | |
DK1005540T3 (da) | IKK-beta-proteiner, nukleinsyrer og fremgangsmåder | |
DE60140156D1 (de) | Verfahren zur Erneuerung von Diffusionsschichten auf Superlegierungen | |
DE69323983D1 (de) | Methode zur Modifizierung des Fettdruckes von Buchstaben | |
DE3587875D1 (de) | Rekombinantverfahren zur herstellung von serinproteaseinhibitoren, sowie dns-sequenzen dazu. | |
DE69433243D1 (de) | Verwendunf von ApoE zum Binden von TAU und MAP2c Proteinen und zur Behandlung von Alzheimer's Krankheit | |
PT914419E (pt) | Ratinhos transgenicos capazes de expressar o factor de inibicao de leucemia | |
ATE230414T1 (de) | Mimetika von beta-faltblatt und verfahren zur verwendung davon | |
ATE417504T1 (de) | Verfahren zur bekämpfung von käfern | |
DE69532725D1 (de) | Methode zur direkter klonierung von nukleasegenen in e.coli | |
DE60111620D1 (de) | Aktiviertes protein c zur behandlung von pankreatitis | |
ATE283703T1 (de) | Neurodegenerative-erkrankung verwandtes gen | |
DE602004001047D1 (de) | Phospholipidester von Clofarabin | |
BR0211130A (pt) | Plantas transgênicas que expressam proteìnas de ligação da cobalamina | |
ATE278014T1 (de) | Target zur behandlung von atherosklerose, fettleibigkeit und diabetis typ ii | |
DE68910036D1 (de) | Luciferase-Gen und neue rekombinante DNA sowie Verfahren zur Herstellung von Luciferase. | |
DE50004899D1 (de) | Verfahren zur Verringerung des Chlorgehaltes von organischen Isocyanaten | |
NO20001180L (no) | Keramikkakkel | |
ATE382054T1 (de) | Verwendung von oxytocinfragmenten zur herstellung einer pharmazeutischen zusammensetzung zum bewirken von eustasis | |
DE69521281D1 (de) | Verfahren zur Herstellung von menschlichem oder humanem Matrilysin mittels rekombinanter DNA. | |
DK2186898T3 (da) | Blomstrings-induktion |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1049767 Country of ref document: EP |